Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

XGEVA® (Denosumab) Granted Marketing Authorization in the European Union

July 15, 2011 By Bio-Medicine.Org

THOUSAND OAKS, Calif., July 15, 2011 /PRNewswire/ — Amgen
(NASDAQ: AMGN) today announced that the European Commission (EC)
has granted marketing authorization for XGEVA® (denosumab) for
the prevention of skeletal-related events (SREs) (pathological
fracture, radiation to bone, spinal cord compression or surgery to
bone) in adults with bone metastases from solid tumors. This
approval of XGEVA applies to all 27 European Union (EU) member
states. The EC also granted XGEVA an additional year of data and
market exclusivity in the EU since the indication was considered
new for denosumab and based on the significant clinical benefit of
XGEVA in comparison with existing therapies.

Bone metastases, the spread of cancer to the bones, are a common
and serious concern for patients with advanced cancer and present a
burden to the healthcare system. Weakened bones due to metastases
can lead to SREs. The primary goal of treatment for bone metastases
is to prevent the occurrence of these debilitating and costly
SREs.

“Skeletal-related events associated with bone metastases are
truly devastating and painful for patients living with cancer, and
today’s approval of XGEVA marks a real advance,” said Professor
Ingo J. Diel, M.D., Institute for Gynecological Oncology, SPGO,
Mannheim, Germany. “In clinical trials XGEVA demonstrated sustained
protection from SREs and also delayed the progression of pain.
These factors will make a genuine difference in the lives of
patients living with advanced cancer.”

The marketing authorization for XGEVA is based on three pivotal,
Phase 3 head-to-head trials that evaluated the effectiveness of
XGEVA versus zoledronic acid at delaying SREs. The SRE clinical
program for XGEVA spanned more than 50 tumor types in over 5,700
patients. In the SRE trials, XGEVA demonstrated a clinically
meaningful improvement in preventing SREs compared to zoledronic
acid. In these trials, XGEVA was administered every four weeks as a
120 mg subcu

‘/>”/>

SOURCE

Related Articles Read More >

DeepWell Digital Therapeutics Mike Wilson Ryan Douglas
How DeepWell is developing video games as tools for treating medical conditions
A woman with a small, handheld device in her lap with tubes that look like earphones plugged into her ears.
Ear-puffing device for migraine treatment wins FDA breakthrough designation
Abbott
Abbott launches upgraded digital health app for neurostimulation
Catheter delivery could enable better brain implants: Synchron’s neuroscience chief explains how

DeviceTalks Weekly.

May 27, 2022
Quick message - No DTW podcast, but plenty else to listen to over this weekend and next week.
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech